Last reviewed · How we verify
AGN-199201 Dose B — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
AGN-199201 Dose B (AGN-199201 Dose B) — Allergan. AGN-199201 Dose B is a drug that targets the molecular target to exert its therapeutic effect.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| AGN-199201 Dose B TARGET | AGN-199201 Dose B | Allergan | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- AGN-199201 Dose B CI watch — RSS
- AGN-199201 Dose B CI watch — Atom
- AGN-199201 Dose B CI watch — JSON
- AGN-199201 Dose B alone — RSS
Cite this brief
Drug Landscape (2026). AGN-199201 Dose B — Competitive Intelligence Brief. https://druglandscape.com/ci/agn-199201-dose-b. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab